APSIS Therapeutics, Ltd. is a biopharmaceutical company researching and developing novel molecules for treatment of infectious diseases. Our goal is to better people’s lives by developing first or better therapeutic solutions for unmet human medical needs.


APSIS owns proprietary bcProtideTM prodrug technology ensuring that the active agent is being efficiently generated within the diseased cells (tumors and infected cells) from its prodrugs. APSIS drug discovery programs are based on its growing libraries of modified nucleosides and nucleotides, and its new prodrug technology for better drug efficacy, low toxicity, and cell specific delivery.


Other discovery platforms include functional oligonucleotide-protein gene cleaving complexes (Cas9-lgRNATM) targeting viral DNAs for curing latent and/or chronic viral infections.

APSIS Therapeutics, LTD.

PO Box 954,

Guilderland, NY 12084-0954

E-mail: info@apsisglobal.com






©2010–2020 Apsis Therapeutics, Ltd. All rights reserved.

To Better Lives with our Sciences